RSS Merit Medical's Wrapsody Cell-Impermeable Endoprosthesis Receives FDA Pre-market Approval

Currently reading:
 RSS Merit Medical's Wrapsody Cell-Impermeable Endoprosthesis Receives FDA Pre-market Approval

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,205
Likes
1,915
Credits
32,754©
Cash
0$
Merit Medical Systems, Inc. (MMSI) announced on Friday that the FDA has granted premarket approval for its Wrapsody Cell-Impermeable Endoprosthesis, paving the way for its U.S. market launch in 2025. This device is specifically engineered to maintain long-term vessel patency for dialysis patients who require a vascular access point, such as an arteriovenous (AV) fistula or AV graft, typically in the arm. According to findings from the Wrapsody WAVE pivotal trial, patients with AV grafts treated for dialysis outflow lesions using the Wrapsody device achieved target lesion primary patencies of 89.8 percent and 82.0 percent at the six-month mark. Meanwhile, Merit Medical's shares are currently trading at $98.40 on the Nasdaq, reflecting a 2.22 percent increase.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom